Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pertuzumab zuvotolimod (SBT6050)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ARS Pharma

Drug class:

HER2-targeted antibody-drug conjugate, TLR8 agonist

Related drugs:

‹

imiquimod intravesical (0)

TransCon TLR7/8 Agonist (0)

ado-trastuzumab emtansine (97)

fam-trastuzumab deruxtecan-nxki (90)

disitamab vedotin (27)

trastuzumab duocarmazine (6)

PF-06804103 (4)

MF-TTZ-MMAE (1)

imiquimod intravesical (0)

TransCon TLR7/8 Agonist (0)

›

HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3